FPM and Chronic Pain MedsCheck

15 June 2022

The faculty has lodged a submission with Australia's Medical Services Advisory Committee about the Chronic Pain MedsCheck trial.

The FPM submission details the faculty's concerns about a $A20 million trial that enabled selected Australian pharmacies to give chronic pain consultations to patients.

"It remains our view that direct payment of public funds to pharmacists to support an unproven one-dimensional treatment intervention would be neither in the best interests of people experiencing chronic pain nor in the interests of the reputation of the pharmacy profession," the submission says.

"We maintain that while it is appropriate for pharmacists to concentrate on the pharmaceutical aspects of a pain care plan, it is inappropriate for that to occur in the absence of consultation with prescribers and other members of the patient’s treatment team." 

The faculty believes the evaluation study of the trial is flawed.


Last updated 10:09 21.06.2022